HK Inno.N and Pfizer partner to distribute COVID-19 vaccine

Companies sign copromotion agreement to distribute‘Comirnaty® LP.8.1 Prefilled Syringe (SARS-CoV-2 mRNA Vaccine)’

Partnership expands from the private market and NIP distribution to co-promotion within the National Immunization Program

HK inno.N (CEO Dal-Won Kwak) announced on the 4th that it has signed a co-promotion agreement with Pfizer Korea (CEO Dong-Wook Oh) for the 2025–2026 season distribution of the new COVID-19 variant vaccine, Comirnaty LP.8.1 Prefilled Syringe (SARS-CoV-2 mRNA Vaccine), as part of the National Immunization Program (NIP).

 

Last year, HK inno.N was responsible for the private distribution of Comirnaty JN1 Injection (single-dose, bretobameran, SARS-CoV-2 mRNA vaccine).

 

More recently, the company has also been in charge of distribution for the government-funded NIP program, which targets high-risk groups such as seniors aged 65 and older and immunocompromised individuals, a market valued at approximately KRW 200 billion.

 

Through this co-promotion agreement, HK inno.N and Pfizer Korea have expanded their partnership to include promotional activities for those included in the National Immunization Program.

 

Comirnaty® LP.8.1 Prefilled Syringe received approval from the MFDS on January 29 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older.

 

The vaccine is administered as a single 0.3 mL intramuscular injection, regardless of previous COVID-19 vaccination history.

 

For individuals who have received prior COVID-19 vaccination, the new shot should be given at least three months after the last dose.

 

HK inno.N CEO Dal-Won Kwak said, “Based on our sales and distribution capabilities, we will contribute to the stable supply of Comirnaty® LP.8.1 Prefilled Syringe and to the improvement of public health in Korea.